⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4076012 | 0.71 | — | — | |
| SCHEMBL154015 | 0.69 | — | — | |
| SCHEMBL6726221 | 0.69 | — | — | |
| SCHEMBL9034571 | 0.69 | — | — | |
| SCHEMBL10370692 | 0.67 | — | — | |
| SCHEMBL534990 | 0.65 | — | — | |
| SCHEMBL27611845 | 0.65 | — | — | |
| SCHEMBL824974 | 0.65 | — | — | |
| SCHEMBL194571 | 0.65 | — | — | |
| SCHEMBL20237098 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166669-A1 | QUINAZOLINE AMINE DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC. | 2024-05-23 | — | — | US | disclosed |
| EP-4301363-A1 | QUINAZOLINE AMINE DERIVATIVES AS KRAS INHIBITORS | Nikang Therapeutics, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| CN-117255684-A | Quinazolinamine derivatives as KRAS inhibitors | 尼坎治疗公司 | 2023-12-19 | — | — | CN | disclosed |
| CN-111566109-B | 2,4,6, 7-tetrahydropyrazolo [4,3-d ] pyrimidin-5-one derivatives and related compounds for the treatment of vasculitis and inflammatory diseases | 爱杜西亚药品有限公司 | 2023-07-11 | — | — | CN | disclosed |
| US-20230192708-A1 | 2,4,6,7-TETRAHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS FOR TREATING VASCULITIS AND INFLAMMATORY DISEASES | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-06-22 | — | — | US | disclosed |
| US-11608341-B2 | Substituted tetrahydropyrazolo[3,4-d]pyrimidines and tetrahydropyrazolo[4,3-d]pyrimidines as C5A receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2023-03-21 | — | — | US | disclosed |
| US-20200369672-A1 | 2,4,6,7-TETRAHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS FOR TREATING VASCULITIS AND INFLAMMATORY DISEASES | IDORSIA PHARMACEUTICALS LTD. (CH) | 2020-11-26 | — | — | US | disclosed |
| EP-3737684-A1 | 2,4,6,7-TETRAHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS FOR TREATING VASCULITIS AND INFLAMMATORY DISEASES | Idorsia Pharmaceuticals Ltd (CH) | 2020-11-18 | — | — | EP | disclosed |
| CN-111566109-A | 2,4,6, 7-tetrahydropyrazolo [4,3-d ] pyrimidin-5-one derivatives and related compounds as C5a receptor modulators for the treatment of vasculitis and inflammatory diseases | 爱杜西亚药品有限公司 | 2020-08-21 | — | — | CN | disclosed |
| EP-1829876-A1 | NITROGENEOUS TRICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-11-02 | — | — | US | disclosed |